Germline mutations of inhibins in early-onset ovarian epithelial tumors

Isabelle Tournier, Régine Marlin, Kelly Walton, Françoise Charbonnier, Sophie Coutant, Jean-Christophe Théry, Camille Charbonnier, Cailyn Spurrell, Myriam Vezain, Lorena Ippolito, Gaëlle Bougeard, Horace Roman, Julie Tinat, Jean-Christophe Sabourin, Dominique Stoppa-Lyonnet, Olivier Caron, Brigitte Bressac-de Paillerets, Dominique Vaur, Mary-Claire King, Craig HarrisonThierry Frebourg

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

To identify novel genetic bases of early-onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancer who presented metastatic serous ovarian adenocarcinomas at 21 years of age. We identified a single de novo mutation (c.1157A>G/p.Asn386Ser) within the INHBA gene encoding the βA-subunit of inhibins/activins, which play a key role in ovarian development. In vitro, this mutation alters the ratio of secreted activins and inhibins. In a second patient with early-onset serous borderline papillary cystadenoma, we identified an unreported germline mutation (c.179G>T/p.Arg60Leu) of the INHA gene encoding the α-subunit, the partner of the βA-subunit. This mutation also alters the secreted activin/inhibin ratio, by disrupting both inhibin A and inhibin B biosynthesis. In a cohort of 62 cases, we detected an additional unreported germline mutation of the INHBA gene (c.839G>A/p.Gly280Glu). Our results strongly suggest that inhibin mutations contribute to the genetic determinism of epithelial ovarian tumors.
Original languageEnglish
Pages (from-to)294-297
Number of pages4
JournalHuman Mutation
Volume35
Issue number3
DOIs
Publication statusPublished - Mar 2014
Externally publishedYes

Keywords

  • Activin
  • Cancer
  • Exome
  • INHA
  • INHBA
  • Inhibin
  • Ovary

Cite this